The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries.
Bertalan NémethWim G GoettschFinn Børlum KristensenOresta PiniazhkoMirjana HuićTomáš TesařDragana AtanasijevicIga LipskaZoltán KalóPublished in: Expert review of pharmacoeconomics & outcomes research (2020)
Joint clinical assessments reduce duplication of efforts based on appropriate scientific rationale. On the other hand, recent examples show that relying on judgments of HTA agencies from wealthier countries with potentially different health-care priorities can lead to suboptimal allocation decisions. In the short term, some stakeholders may benefit from ignoring transferability, but it will ultimately lead to limited access in other disease areas.